These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 24746736)

  • 21. [The optimal duration of anticoagulant treatment following pulmonary embolism].
    Couturaud F
    Rev Mal Respir; 2011 Dec; 28(10):1265-77. PubMed ID: 22152935
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Polish guidelines for the prevention and treatment of venous thromboembolism: 2009 update].
    Zawilska K; Jaeschke R; Tomkowski W; Mayzner-Zawadzka E; Nizankowski R; Olejek A; Pasierski T; Torbicki A; Undas A; Jawień A; Gajewski P; Sznajd J; Brozek J;
    Pol Arch Med Wewn; 2009; 119 Suppl 1():1-69. PubMed ID: 19841614
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An open-label comparison of the efficacy and safety of certoparin versus unfractionated heparin for the prevention of thromboembolic complications in acutely ill medical patients: CERTAIN.
    Schellong SM; Haas S; Greinacher A; Schwanebeck U; Sieder C; Abletshauser C; Bramlage P; Riess H
    Expert Opin Pharmacother; 2010 Dec; 11(18):2953-61. PubMed ID: 20950224
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevention and treatment of venous thromboembolism in pregnancy.
    James AH
    Clin Obstet Gynecol; 2012 Sep; 55(3):774-87. PubMed ID: 22828110
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Venous thromboembolism and cancer].
    Meyer G
    Rev Prat; 2015 Feb; 65(2):216-9. PubMed ID: 25939227
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A cross-sectional evaluation of venous thromboembolism risk and use of venous thromboembolism prophylaxis in hospitalized patients in Senegal.
    Bâ SA; Badiane SB; Diop SN; Diouf FS; Fall D; Ka MM; Kane A; Ndiaye M;
    Arch Cardiovasc Dis; 2011 Oct; 104(10):493-501. PubMed ID: 22044701
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.
    Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS
    Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The management of venous thromboembolism in cancer patients.
    Dolan S; Fitch M
    Br J Nurs; 2007 Nov 22-Dec 12; 16(21):1308-12. PubMed ID: 18073666
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Thromboprophylaxis of venous thromboembolism].
    Kobayashi T
    Nihon Rinsho; 2014 Jul; 72(7):1303-8. PubMed ID: 25163326
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Secondary prevention of venous thromboembolism in patients with cancer].
    Meyer G
    Rev Prat; 2011 Nov; 61(9):1249-51. PubMed ID: 22308809
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low-molecular-weight heparins for cancer-associated thrombosis: Adherence to clinical practice guidelines and patient perception in TROPIQUE, a 409-patient prospective observational study.
    Cajfinger F; Debourdeau P; Lamblin A; Benatar V; Falvo N; Benhamou Y; Sevestre MA; Farge-Bancel D;
    Thromb Res; 2016 Aug; 144():85-92. PubMed ID: 27318244
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A retrospective analysis of the effectiveness of low molecular weight heparin for venous thromboembolism prophylaxis in trauma patients.
    Gritsiouk Y; Hegsted DA; Schlesinger P; Gardiner SK; Gubler KD
    Am J Surg; 2014 May; 207(5):648-51; discussion 651-2. PubMed ID: 24560359
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Thromboembolism and antithrombotic management in pregnancy].
    Pajor A
    Orv Hetil; 2011 May; 152(21):815-21. PubMed ID: 21546339
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Venous thrombo-embolic disease in cancer. Low molecular weight heparin indications].
    Nou M; Laroche JP
    J Mal Vasc; 2016 May; 41(3):197-204. PubMed ID: 27146099
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bleeding and venous thromboembolism arising in acutely ill hospitalized medical patients. Findings from the Spanish national discharge database.
    Guijarro R; San Roman C; Arcelus JI; Montes-Santiago J; Gómez-Huelgas R; Gallardo P; Monreal M
    Eur J Intern Med; 2014 Feb; 25(2):137-41. PubMed ID: 24200547
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Questionnaire for assessing the risk of venous thromboembolism in hospitalized surgical and non-surgical patients in the 4th Hungarian antithrombotic guideline entitled "Risk reduction and treatment of venous thromboembolism"].
    Dávid M; Losonczy H; Udvardy M; Boda Z; Blaskó G; Tar A; Pfliegler G
    Orv Hetil; 2010 Aug; 151(34):1365-74. PubMed ID: 20705551
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-life practices for preventing venous thromboembolism in multiple myeloma patients: a cohort study from the French health insurance database.
    Palmaro A; Rougé-Bugat ME; Gauthier M; Despas F; Moulis G; Lapeyre-Mestre M
    Pharmacoepidemiol Drug Saf; 2017 May; 26(5):578-586. PubMed ID: 28198064
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Direct oral anticoagulants and cancer-associated VTE: good for all, or just some?
    Carrier M; Wang TF
    Blood; 2020 Aug; 136(6):669-673. PubMed ID: 32575112
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anticoagulation therapy for prevention and treatment of venous thromboembolic events in cancer patients: a review of current guidelines.
    Petersen LJ
    Cancer Treat Rev; 2009 Dec; 35(8):754-64. PubMed ID: 19762155
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevention of venous thromboembolism in the cancer surgical patient.
    Kakkar AK
    J Clin Oncol; 2009 Oct; 27(29):4881-4. PubMed ID: 19738112
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.